Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADXS11-001 in Persistent or Recurrent Cervical Cancer
NCT01266460Phase 2Completed
- Sponsor
- GOG Foundation
- Start
- May 2011
- Primary completion
- Oct 2018
- Modality
- Gene Editing, Gene Silencing, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of axalimogene filolisbac in Cervical Cancer (CC), sponsored by GOG Foundation. Started May 2011; status: completed.
02
Drugs
axalimogene filolisbac
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT01266460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01266460.